Simponi (Golimumab) 50mg/0.5mL Autoinjector (Smartject)

$6,495.00

Drug Info: ApoThera Drug Disease Clinical Support App

Ulcerative Colitis
Induction Dose
– 200 mg SC at week 0, then 100 mg at week 2
Maintenance Dose
– 100 mg SC every 4 week
– Prescription Required
– Free Next Day Delivery to Anywhere in CA and NY
– Free Same Day Delivery within 30-Mile Radius of ApoThera
– Concierge Pharmacy; Do NOT Accept Insurance
– Annual Concierge Membership Fee: $300
– Accept Credit Cards, Debit Cards, Apple Pay and Zelle
– Do NOT accept manufacturer coupons
 
Physicians may send E-Prescriptions (E-Scripts) to:
ApoThera
45 Post, 2nd Floor
Irvine, CA 92618
Phone: (949)387-7711
Fax:      (949)387-7712
Manufacturer: Janssen
NDC: 57894-0070-02 Category:

1 Syringe = 1 Unit

Description

Drug Info: ApoThera Drug Disease Clinical Support App

SC Administration
– Warm by sitting at room temperature for 30 min; do NOT heat or microwave
– If multiple injections required, administer at different site on the body

– Injection sites: Front of thighs (recommended), lower abdomen (except for a 2-inch area right around the navel); back of the upper arms (only if someone else is administering it)
– Rotate injection sites for each administration
– Do not administer in area where the skin is tender, bruised, red, or hard
 
Storage
– Refrigerate Simponi at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light until the time of use
– Do not freeze.
– Do not shake.
– Do not use Simponi beyond the expiration date (EXP) on the carton or the expiration date on the prefilled syringe (observed through the viewing window) or the prefilled SmartJect autoinjector.
– If needed, Simponi may be stored at room temperature up to 77°F (25°C) for a maximum single period of 30 days in the original carton to protect from light.
– Once a syringe or autoinjector has been stored at room temperature, do not return the product to the refrigerator.
– If not used within 30 days at room temperature, discard Simponi
Monitoring
– CBC with differential
– Latent TB screening (prior to initiating and periodically during therapy)
– HBV screening (prior to initiating [all patients]; during and for several months following therapy [HBV carriers])
– Monitor improvement of symptoms and physical function assessments
– Signs/symptoms of infection (prior to, during, and following therapy)
– Signs/symptoms/worsening of heart failure signs and symptoms of hypersensitivity reaction
– Symptoms of lupus-like syndrome
– Signs/symptoms of malignancy (splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) including periodic skin examination